Suchergebnisse - "Podzamczer, Daniel"

PubPharm (29)

1

Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM) : a randomised non-inferiority trial

enthalten in: The lancet. HIV | 2021

von Rojas, J. | de Lazzari, E. | Negredo, E. | +14

CommentIn: Lancet HIV. 2021 Aug;8(8):e454-e455. - PMID 34358493

2

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection : week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

enthalten in: The lancet. HIV | 2020

von Orkin, C. | DeJesus, E. | Sax, P. | +20

CommentIn: Lancet HIV. 2020 Jun;7(6):e374-e375. - PMID 32504568

3

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate : a pooled analysis of 26 clinical trials

enthalten in: AIDS (London, England) | 2019

von Gupta, S. | Post, F. | Arribas, J. | +21

4

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD) : 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

enthalten in: The lancet. HIV | 2018

von Molina, J. | Squires, K. | Sax, P. | +113

CommentIn: Lancet HIV. 2018 May;5(5):e200-e201. - PMID 29592841

5

Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults : a randomised, double-blind, active-controlled, non-inferiority phase 3 trial

enthalten in: The lancet. HIV | 2018

von Winston, A. | Post, F. | DeJesus, E. | +14

CommentIn: Lancet HIV. 2018 Apr;5(4):e156-e157. - PMID 29475803

6

Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components

enthalten in: Enfermedades infecciosas y microbiologia clinica (English ed.) | 2018

von Llibre, J. | de Lazzari, E. | Molina, J. | +7

7

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection

enthalten in: HIV clinical trials | 2017

von Yong, C. | Gathe, J. | Knecht, G. | +9

8

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489) : a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

enthalten in: Lancet (London, England) | 2017

von Gallant, J. | Lazzarin, A. | Mills, A. | +14

9

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients : A Randomized, Multinational, Multicenter Trial

enthalten in: PloS one | 2016

von Cooper, D. | Cordery, D. | Zajdenverg, R. | +87

10

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE) : a randomised, open-label, non-inferiority trial

enthalten in: The Lancet. Infectious diseases | 2015

von Arribas, J. | Girard, P. | Landman, R. | +118

CommentIn: Lancet Infect Dis. 2015 Jul;15(7):748-9. - PMID 26062879